This Specificity Enhanced Bi-specific Antibody (SEBA) is of the oncology therapeutic class that binds functional proteins on the surface of cells in this molecule to block growth signals that cancer cells depend on for survival. The SEBA technology allows the molecule to use one surface protein for specific targeting of the cancer, and then block a second protein, even if it is not specific for the cancer.

‍The bi-specific SEBA SI-B001 is built on a tetravalent platform having two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival. The SI-B001 primary mechanism of action is the blocking of EGFR and HER3 signals to cancer cells, and secondarily, through a wt FC receptor mediating innate immune effector functions toward the cancer cells.

SI-B001 is currently being evaluated as a single agent and in combination in clinical trials enrolling patients with a variety of solid tumor types.